Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 31, 2025Communications ChemistryOpen Access

Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACs

View Full Paper
Ask AI
Bookmark
Share

Authors

AVAndré T. S. VicenteSMSara MouraJSJorge A. R. Salvador

Discussion

Loading...

Member takes

Overview

Review highlights recent advances in cereblon-based PROTACs, emphasizing biological evaluation and clinical trials.

Key Points

  • Cereblon-based PROTACs represent a novel therapeutic strategy for various diseases, notably cancer and neurological disorders.
  • Recent clinical trials have shown promising results, indicating the potential of PROTACs for effective protein degradation.
  • The review analyzes challenges and advancements in the design and synthesis of cereblon-based PROTACs for drug development.
  • Insights from drug discovery are integrated to guide future research directions for cereblon-based PROTACs.

Cite This Study

Vicente et al. (2025) studied this question.

synapsesocial.com/papers/689a0c5fe6551bb0af8cf6b2https://doi.org/10.1038/s42004-025-01598-9
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Development of a Partial Proteolysis Targeting Chimera Library Based on Achiral Cereblon E3 Ligase Ligands and its Application for Bruton's Tyrosine Kinase Degraders2025
  2. 2Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions2025
  3. 3Nanotechnology-Based Strategies for Overcoming Clinical Limitations of PROTACs in Cancer Therapy2025
  4. 4Proteolysis Targeting Chimera (PROTACs) in Cancer: From Molecular Mechanisms to Therapeutic Opportunities2025
  5. 5FDA-approved kinase inhibitors in PROTAC design, development and synthesis2025